COO
The Cooper Companies, Inc.81.04
-0.49-0.6%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q1 '26
Japan drag, Q3 Asia rebound
Q&A pinpointed Japan legacy hydrogel share losses to competitors as the precise drag on Asia Pac and Q1 CooperVision growth, but management detailed new MyDay contracts across regions, product launches, and leadership upgrades for a Q3 turnaround. Pricing stabilized positively outside Asia pressures, with MiSight gaining strong early traction in Japan amid 77% childhood myopia. Fertility recovery confirmed in U.S./Europe cycles yet China weakens and Middle East (2% sales) risks linger. Margins prove durable via AI efficiencies. Japan hurts now. Investors watch Asia execution.
Key Stats
Market Cap
16.11BP/E (TTM)
43.34Basic EPS (TTM)
1.87Dividend Yield
0%Recent Filings
10-Q
Q1 FY2026 results
Cooper Companies posted Q1 FY2026 net sales of $1,024.1M, up 6% y/y from $964.7M, with CooperVision surging 8% to $695.1M on toric/multifocal and MiSight strength while CooperSurgical grew 3% to $329.0M. Gross margin held at 68%; operating income jumped 17% y/y to $212.8M, diluted EPS rose to $0.66 from $0.52 on 196.7M shares. Operating cash flow hit $260.9M; free cash flow $158.7M (derived). Cash sits at $124.9M, total debt $2,499.7M with $1,367.0M revolver availability and covenant compliance. Repurchased $92.5M in shares. U.K. tax dispute looms with possible £71.7M hit.
8-K
Q1 revenue up 6%, guidance raised
CooperCompanies reported Q1 revenue of $1.024 billion, up 6% or 3% organically, with GAAP EPS at $0.66 (up 27%) and non-GAAP EPS at $1.10 (up 20%). CooperVision surged 8% to $695.1 million on toric/multifocal strength, while CooperSurgical grew 3% to $329 million; margins expanded via reorganization synergies. Raised FY2026 guidance to $4.306-$4.346 billion revenue and $4.58-$4.66 non-GAAP EPS. Cash flow fuels repurchases.
8-K
Cooper extends $950M term loans
Cooper Companies extended $950M of its $1.5B term loans to February 3, 2031 while $550M matures December 17, 2026. Lenders dropped credit spread adjustments and raised incremental term loan cap to the greater of $1.365B and 100% of EBITDA. Pricing now ties optionally to leverage or debt ratings. Lenders refinanced on flexible terms.
8-K
Cooper inks activist board deal
CooperCompanies struck a cooperation deal with activist Browning West on December 22, 2025, appointing Walter M. Rosebrough, Jr. to its board and nominating committee effective January 3, 2026, while committing to add one more independent medtech director by June 30. Browning West, holding 4.0% of shares, agreed to standstill curbs and board support through mid-2027. Board stays at ten max. Deal reimburses Browning West $400,000.
8-K
CFO adds accounting officer role
The Cooper Companies' CFO Brian G. Andrews assumed principal accounting officer duties on December 9, 2025, succeeding Agostino Ricupati, who stays on as SVP Tax. Andrews, CFO since 2018, takes the added role with no compensation change or related arrangements. Smooth internal shift. No family ties or reportable transactions disclosed.
IPO
Website
Employees
Sector
Industry
ALC
Alcon Inc.
79.02-0.17
BLCO
Bausch + Lomb Corporation
16.98-0.11
HOLX
Hologic, Inc.
75.02-0.17
ISRG
Intuitive Surgical, Inc.
554.58-4.94
OMI
Owens & Minor, Inc.
3.10+0.09
POCI
Precision Optics Corporation, I
4.20-0.07
RXST
RxSight, Inc.
12.76+0.24
SGHT
Sight Sciences, Inc.
8.39+0.08
STAA
STAAR Surgical Company
24.80+1.24
WRBY
Warby Parker Inc.
26.65-0.19